Literature DB >> 12824799

Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine.

Fausto Baldanti1, Stefania Paolucci, Giovanni Maga, Nazzarena Labo, Ulrich Hübscher, Alexander Yu Skoblov, Lyubov Victorova, Silvio Spadari, Lorenzo Minoli, Giuseppe Gerna.   

Abstract

Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12824799     DOI： 10.1097/00002030-200307040-00021

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  9 in total

1.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.

Authors:  Stefania Paolucci; Fausto Baldanti; Giovanni Maga; Reynel Cancio; Maurizio Zazzi; Maurizio Zavattoni; Antonella Chiesa; Silvio Spadari; Giuseppe Gerna
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  Soumi Gupta; Signe Fransen; Ellen E Paxinos; Eric Stawiski; Wei Huang; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

5.  Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

6.  The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.

Authors:  Zandrea Ambrose; Brian D Herman; Chih-Wei Sheen; Shannon Zelina; Katie L Moore; Gilda Tachedjian; Dwight V Nissley; Nicolas Sluis-Cremer
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

7.  Optimal cytoplasmic transport in viral infections.

Authors:  Maria R D'Orsogna; Tom Chou
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

8.  N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Authors:  Soo-Huey Yap; Chih-Wei Sheen; Jonathan Fahey; Mark Zanin; David Tyssen; Viviane Dias Lima; Brian Wynhoven; Michael Kuiper; Nicolas Sluis-Cremer; P Richard Harrigan; Gilda Tachedjian
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

9.  Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.

Authors:  Wei Guo; Jingwan Han; Daomin Zhuang; Siyang Liu; Yongjian Liu; Lin Li; Hanping Li; Zuoyi Bao; Fujiang Wang; Jingyun Li
Journal:  Virol J       Date:  2015-11-14       Impact factor: 4.099
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.